If I may, in speaking to that first question, and probably a little to the second question, Dr. Beaudet mentioned earlier about personalized medicine and the work they're doing with Genome Canada. A great innovation is that they've started to recognize that it's not just about producing the new technology; it's about having somebody actually wanting to use it and pay for it.
With regard to these demonstration projects that he talked about, I met about two weeks ago with the CEO of Genome Canada and Genome B.C. These are technologies that we might not see for four or five years, yet they're already starting to have the dialogue with us about how they can make these products useful, from a payer's perspective.
I think that's an interesting approach, rather than just introducing this and making us determine whether we want to pay for it at the time of its introduction.